EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

OAS 16 - Insights into Hereditary Angioedema management

Saturday 01 Jun, 16:45 PM - 18:15 PM Valencia, Spain
Bilbao Oral Abstract Sessions
16:45 001703
Characteristics of Nailfold Videocapillaroscopy in Hereditary Angioedema due to C1 Inhibitor Deficiency
16:57 000420
A sensitive and specific assay to characterize plasma kallikrein activity in plasma from hereditary angioedema (HAE) patients
17:09 000326
Impact of hereditary angioedema on dental care: from a study of 112 French patients
17:21 000492
Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
17:33 000493
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
17:45 001391
Health-related quality of life in hereditary angioedema patients using subcutaneous plasma derived C1 inhibitor therapy in Canada
17:57 001398
Real-life features of hereditary angioedema attacks: first results from the registry supported by ITACA (Italian network for hereditary and acquired angioedema)